Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Stiefel, F.
Right arrow Articles by Guex, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stiefel, F.
Right arrow Articles by Guex, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 7:135-138, 1996
© 1996 European Society for Medical Oncology

other

Palliative and supportive care: At the frontier of medical omnipotence*

F. Stiefel and P. Guex

Division Autonome de Médecine Psycho-Sociale, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

Cancer patients have physical, social, spiritual and emotional needs. They may suffer from severe physical symptoms, from social isolation and a sense of spiritual abandonment, and emotions such as sadness and anxiety, or feelings of deception, helplessness, anger and guilt. In some of them, the disease is rapidly progressive and they ultimately die. Their demanding care evokes intense feelings in health care providers, the more so since these incurable patients represent a challenge, which can be characterized as one of ‘medical onmipotence’. It may be assumed that the way health care providers cope with these circumstances profoundly influences the way these patients are cared for. Attitudes regarding the emerging heterogeneous movement of palliative and supportive care and its different models of implementation can be viewed from this vantage point. Here we look at these interrelations and discuss the potential pitfalls if they are ignored and remain unexamined.

cancer, palliative care, psycho-oncology, supportive care


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
R. Schnell, P. Borchmann, J. O. Staak, J. Schindler, V. Ghetie, E. S. Vitetta, and A. Engert
Clinical evaluation of ricin A-chain immunotoxins in patients with Hodgkin's lymphoma
Ann. Onc., May 1, 2003; 14(5): 729 - 736.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Schnell, O. Staak, P. Borchmann, C. Schwartz, B. Matthey, H. Hansen, J. Schindler, V. Ghetie, E. S. Vitetta, V. Diehl, et al.
A Phase I Study with an Anti-CD30 Ricin A-Chain Immunotoxin (Ki-4.dgA) in Patients with Refractory CD30+ Hodgkin's and Non-Hodgkin's Lymphoma
Clin. Cancer Res., June 1, 2002; 8(6): 1779 - 1786.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. Barth, M. Huhn, B. Matthey, S. Tawadros, R. Schnell, T. Schinkothe, V. Diehl, and A. Engert
Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice
Blood, June 15, 2000; 95(12): 3909 - 3914.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.